JP2020537672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537672A5 JP2020537672A5 JP2020521991A JP2020521991A JP2020537672A5 JP 2020537672 A5 JP2020537672 A5 JP 2020537672A5 JP 2020521991 A JP2020521991 A JP 2020521991A JP 2020521991 A JP2020521991 A JP 2020521991A JP 2020537672 A5 JP2020537672 A5 JP 2020537672A5
- Authority
- JP
- Japan
- Prior art keywords
- independently selected
- alkyl
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 150000003839 salts Chemical class 0.000 description 13
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023093474A JP7654031B2 (ja) | 2017-10-20 | 2023-06-06 | 炎症性障害の治療のための新規化合物及びその医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1717260.2A GB201717260D0 (en) | 2017-10-20 | 2017-10-20 | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
| GB1717260.2 | 2017-10-20 | ||
| PCT/EP2018/077677 WO2019076716A1 (en) | 2017-10-20 | 2018-10-11 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS RELATED THERETO FOR THE TREATMENT OF INFLAMMATORY DISORDERS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093474A Division JP7654031B2 (ja) | 2017-10-20 | 2023-06-06 | 炎症性障害の治療のための新規化合物及びその医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537672A JP2020537672A (ja) | 2020-12-24 |
| JP2020537672A5 true JP2020537672A5 (https=) | 2021-11-11 |
| JP7292271B2 JP7292271B2 (ja) | 2023-06-16 |
Family
ID=60481889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521991A Active JP7292271B2 (ja) | 2017-10-20 | 2018-10-11 | 炎症性障害の治療のための新規化合物及びその医薬組成物 |
| JP2023093474A Active JP7654031B2 (ja) | 2017-10-20 | 2023-06-06 | 炎症性障害の治療のための新規化合物及びその医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093474A Active JP7654031B2 (ja) | 2017-10-20 | 2023-06-06 | 炎症性障害の治療のための新規化合物及びその医薬組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11564923B2 (https=) |
| EP (2) | EP3697784B9 (https=) |
| JP (2) | JP7292271B2 (https=) |
| KR (1) | KR102757425B1 (https=) |
| CN (2) | CN111225916B (https=) |
| AR (1) | AR113784A1 (https=) |
| AU (2) | AU2018350592B2 (https=) |
| CA (1) | CA3079449A1 (https=) |
| CO (1) | CO2020005200A2 (https=) |
| DK (1) | DK3697784T5 (https=) |
| ES (1) | ES2967432T3 (https=) |
| FI (1) | FI3697784T5 (https=) |
| GB (1) | GB201717260D0 (https=) |
| HR (1) | HRP20231315T1 (https=) |
| HU (1) | HUE063998T2 (https=) |
| IL (2) | IL302615B2 (https=) |
| LT (1) | LT3697784T (https=) |
| MA (1) | MA50391B1 (https=) |
| MX (1) | MX2020003863A (https=) |
| MY (1) | MY205443A (https=) |
| PH (1) | PH12020550230A1 (https=) |
| PL (1) | PL3697784T3 (https=) |
| PT (1) | PT3697784T (https=) |
| RS (1) | RS64800B1 (https=) |
| SG (1) | SG11202003516TA (https=) |
| SI (1) | SI3697784T1 (https=) |
| SM (1) | SMT202300377T1 (https=) |
| TW (2) | TWI866258B (https=) |
| WO (1) | WO2019076716A1 (https=) |
| ZA (1) | ZA202002166B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201717260D0 (en) * | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
| AU2020284742B2 (en) * | 2019-05-28 | 2026-03-05 | Mankind Pharma Ltd. | Novel compounds for inhibition of Janus Kinase 1 |
| CA3208361A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| EP4294806A1 (en) | 2021-02-19 | 2023-12-27 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| AU2022222470A1 (en) | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| AU2022310901A1 (en) | 2021-07-12 | 2024-02-22 | Galapagos Nv | Treatment of inflammatory diseases |
| AU2022412835A1 (en) | 2021-12-16 | 2024-06-20 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
| WO2023161326A1 (en) | 2022-02-24 | 2023-08-31 | Galapagos Nv | Compound for use in and methods of treatment of inflammatory diseases |
| WO2023161327A1 (en) | 2022-02-24 | 2023-08-31 | Galapagos Nv | Compound for use in and methods of treatment of inflammatory diseases |
| JP2024082106A (ja) * | 2022-12-07 | 2024-06-19 | 富士通株式会社 | 情報処理プログラム、情報処理方法および情報処理装置 |
| CR20250317A (es) | 2023-01-18 | 2025-08-29 | Galapagos Nv | Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios |
| AU2024209905A1 (en) | 2023-01-19 | 2025-09-04 | Galapagos Nv | Imidazo[4,5-b]pyridine derivatives useful for the treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases and proliferative diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102127078A (zh) * | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
| ES2567552T3 (es) * | 2012-01-30 | 2016-04-25 | Cephalon, Inc. | Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos |
| GB201401086D0 (en) | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2017012647A1 (en) | 2015-07-20 | 2017-01-26 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| AR105400A1 (es) * | 2015-08-04 | 2017-09-27 | Lilly Co Eli | Inhibidores de jak1 |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| GB201717260D0 (en) * | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
-
2017
- 2017-10-20 GB GBGB1717260.2A patent/GB201717260D0/en not_active Ceased
-
2018
- 2018-10-11 FI FIEP18788711.2T patent/FI3697784T5/fi active
- 2018-10-11 MA MA50391A patent/MA50391B1/fr unknown
- 2018-10-11 PT PT187887112T patent/PT3697784T/pt unknown
- 2018-10-11 SM SM20230377T patent/SMT202300377T1/it unknown
- 2018-10-11 IL IL302615A patent/IL302615B2/en unknown
- 2018-10-11 AU AU2018350592A patent/AU2018350592B2/en active Active
- 2018-10-11 US US16/757,189 patent/US11564923B2/en active Active
- 2018-10-11 CN CN201880067863.7A patent/CN111225916B/zh active Active
- 2018-10-11 SG SG11202003516TA patent/SG11202003516TA/en unknown
- 2018-10-11 ES ES18788711T patent/ES2967432T3/es active Active
- 2018-10-11 IL IL273943A patent/IL273943B2/en unknown
- 2018-10-11 CN CN202311478101.5A patent/CN117534670A/zh active Pending
- 2018-10-11 KR KR1020207014284A patent/KR102757425B1/ko active Active
- 2018-10-11 EP EP18788711.2A patent/EP3697784B9/en active Active
- 2018-10-11 EP EP23191626.3A patent/EP4265254A3/en active Pending
- 2018-10-11 HR HRP20231315TT patent/HRP20231315T1/hr unknown
- 2018-10-11 DK DK18788711.2T patent/DK3697784T5/da active
- 2018-10-11 JP JP2020521991A patent/JP7292271B2/ja active Active
- 2018-10-11 RS RS20231045A patent/RS64800B1/sr unknown
- 2018-10-11 SI SI201831002T patent/SI3697784T1/sl unknown
- 2018-10-11 PL PL18788711.2T patent/PL3697784T3/pl unknown
- 2018-10-11 HU HUE18788711A patent/HUE063998T2/hu unknown
- 2018-10-11 MY MYPI2020001882A patent/MY205443A/en unknown
- 2018-10-11 MX MX2020003863A patent/MX2020003863A/es unknown
- 2018-10-11 LT LTEPPCT/EP2018/077677T patent/LT3697784T/lt unknown
- 2018-10-11 CA CA3079449A patent/CA3079449A1/en active Pending
- 2018-10-11 WO PCT/EP2018/077677 patent/WO2019076716A1/en not_active Ceased
- 2018-10-19 TW TW112121026A patent/TWI866258B/zh active
- 2018-10-19 TW TW107136998A patent/TWI805629B/zh active
- 2018-10-19 AR ARP180103068A patent/AR113784A1/es unknown
-
2020
- 2020-04-07 PH PH12020550230A patent/PH12020550230A1/en unknown
- 2020-04-27 CO CONC2020/0005200A patent/CO2020005200A2/es unknown
- 2020-05-04 ZA ZA2020/02166A patent/ZA202002166B/en unknown
-
2022
- 2022-12-27 US US18/146,698 patent/US12472181B2/en active Active
-
2023
- 2023-03-10 AU AU2023201522A patent/AU2023201522B2/en active Active
- 2023-06-06 JP JP2023093474A patent/JP7654031B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537672A5 (https=) | ||
| JP2010523522A5 (https=) | ||
| JP2014531449A5 (https=) | ||
| CA2817317C (en) | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| JP2018528244A5 (https=) | ||
| JP2020529994A5 (https=) | ||
| JP2007507494A5 (https=) | ||
| JP2018115191A5 (https=) | ||
| JP2012518634A5 (https=) | ||
| JP2017520613A5 (https=) | ||
| JP2016525102A5 (https=) | ||
| JP2017511365A5 (https=) | ||
| JP2020526549A5 (https=) | ||
| PH12015500294B1 (en) | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors | |
| JP2013502431A5 (https=) | ||
| JP2019536768A5 (https=) | ||
| JP2023523241A5 (https=) | ||
| FI3697784T3 (fi) | Imidatso[4,5-b]pyridiiniyhdisteet ja niiden farmaseuttiset koostu- mukset tulehduksellisten häiriöiden hoitoa varten | |
| RU2014115476A (ru) | Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ | |
| JP2013544276A5 (https=) | ||
| CN101969951A (zh) | 治疗关节炎的方法 | |
| JP2019516739A5 (https=) | ||
| RU2013136778A (ru) | Ингибиторы гистондезацетилазы, композиции и способы их применения | |
| JP2014530197A5 (https=) | ||
| JP2016525142A5 (https=) |